Angiotensin-II Blockade in Mitral Regurgitation

Mitral regurgitation (MR) is common in the elderly and its prevalence is increasing with the aging of the population. Organic MR, due to primary valvular lesions, initiates a cascade of complications determined by its degree. MR of severe degree is associated with excess mortality and high cardiac morbidity (heart failure, atrial fibrillation). It also causes left ventricular remodeling which induces left ventricular dysfunction, which in turn leads to poor clinical outcome. Surgery can eliminate MR, but carries immediate and long-term risks, especially in the elderly. Therefore, chronically decreasing the degree of MR is a major goal of medical therapy but such an effect is yet unproved because of conflicting results of small and mostly non-randomized series. Our recent preliminary studies suggest that a sustained decrease of degree of MR and improvement of left ventricular remodeling can be achieved with powerful reduction of afterload, obtained in particular with angiotensin-II receptor blockade. Therefore, the present proposal seeks to address gaps of knowledge regarding vasoactive treatment of MR through the verification of the following hypothesis: Hypothesis: Vasoactive therapy using angiotensin-II receptor blocker (Candesartan Cilexetil) weighed against placebo produces a sustained reduction of the consequences of organic MR. The specific aims are that the treatment a) decreases the degree of MR (decreases the regurgitant volume, primary end-point) and b) improves left ventricular remodeling (decreases the end-diastolic volume index, secondary end-point), as compared to placebo.

Study Overview

• Status: Completed
• Conditions: Mitral Regurgitation
• Intervention / Treatment: Drug: Placebo; Drug: Candesartan; Drug: atacand

Detailed Description

Patients with MR organic (intrinsic valve disease), isolated (no other valve disease), moderate or more severe (regurgitant volume *30 mL/beat). A Clinical trial, randomized, placebo controlled, double-blind, without cross-over, of 1 year oral treatment with potent angiotensin-II receptor blockade using 32 mg Candesartan daily. The trial is preceded in all patients by an acute open-label study to determine tolerance and immediate response. The methods used to measure the end-points will be: a) Doppler-Echocardiography for quantitation of the degree of MR (measurement of regurgitant volume) using a combination of three simultaneous methods (quantitative Doppler, quantitative two-dimensional echocardiography, proximal flow convergence) and b) of left ventricular remodeling (end-diastolic volume index measured by echocardiography and by electron beam computed tomography). This single center study seeks to enroll a total of 90 patients. The analysis will be based on intention to treat and compare the regurgitant volume and left ventricular end-diastolic volume index measured after one year of treatment with the active drug or placebo. The results of the trial should provide strong evidence regarding medical treatment of patients with organic MR.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Rochester, Minnesota, United States, 55905'
      • Mayo Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients:

• 18 years old or older, with
• Mitral regurgitation on the basis of Color flow imaging
• Due to organic disease of the mitral valve on the basis of two-dimensional echocardiography
• Isolated (no valve disease other than functional tricuspid regurgitation on the basis of Doppler-Echocardiography)
• Pure (no mitral stenosis by Doppler echocardiography)
• Quantifiable by Doppler-Echocardiographic methods
• Of more than mild degree, defined as regurgitant volume * 30 mL/beat
• Occurring on native valves
• With Two-dimensional echocardiographic imaging allowing assessment of LV remodeling, and
• Asymptomatic (or mildly symptomatic but not considered as candidates for immediate surgery by their attending physician).

Exclusion Criteria:

• Associated aortic valve disease (more than trace aortic regurgitation by color flow imaging or mean gradient *25 mmHg)
• Associated mitral stenosis (mean gradient* 5 mmHg, valve area < 1.5 cm2)
• Associated congenital or pericardial diseases on the basis of Doppler echocardiography
• Intolerance to either AII blockers or Angiotensin converting enzyme inhibitors
• Intolerance to iodine contrast material
• Intolerance to intravenous echographic contrast agents
• Renal failure with creatinine * 2 mg/dl
• Blood pressure below 100 mmHg
• Known renal artery stenosis
• Ongoing therapy with hydralazine, calcium-entry blocking drugs or angiotensin converting enzyme inhibitors
• Known severe comorbidity such as liver disease, malignancy
• Pregnancy (A negative pregnancy test and effective contraceptive methods are required prior to enrollment of females of childbearing potential (not post-menopausal or surgically sterilized)), and
• Patients considered as requiring mitral valve surgery by their attending physician or with previous valve repair or replacement.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: 2; Placebo	Drug: Placebo; Placebo
EXPERIMENTAL: 1; Atacand treatment.	Drug: Candesartan; Maximum vasodilation.; Other Names: atacand; Drug: atacand; maximum vasodilation; Other Names: candesartan

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Tolerance of the medication.	one year

Secondary Outcome Measures

Outcome Measure	Time Frame
Decrease of severity of mitral regurgitation.	1 year

Collaborators and Investigators

• Sponsor: Mayo Clinic
• Investigators: Principal Investigator: Maurice E. Sarano, M.D., Mayo Clinic Foundation

Study record dates

Study Major Dates

• Study Start: August 1, 1998
• Primary Completion (ACTUAL): August 1, 2001
• Study Completion (ACTUAL): August 1, 2001

Study Registration Dates

• First Submitted: December 21, 2007
• First Submitted That Met QC Criteria: January 4, 2008
• First Posted (ESTIMATE): January 7, 2008

Study Record Updates

• Last Update Posted (ESTIMATE): October 15, 2010
• Last Update Submitted That Met QC Criteria: October 14, 2010
• Last Verified: October 1, 2010

More Information

Terms related to this study

• Keywords: valve, mitral, regurgitation
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Valve Diseases; Mitral Valve Insufficiency; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Candesartan; Candesartan cilexetil
• Other Study ID Numbers: 1129-98